Description of Agios Pharmaceuticals Inc's Business Segments
Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing potential therapies for rare genetic diseases and cancer. The companys efforts are primarily centered around its innovative drug discovery platform and its commitment to advancing metabolic therapies.
Segments
1. Rare Genetic Diseases: - Agios has a significant focus on rare genetic disorders, particularly those related to alterations in cellular metabolism. These disorders often require specialized treatments that target the underlying metabolic pathways. The companys pipeline includes therapies specifically aimed at treating conditions like pyruvate kinase deficiency (PK deficiency), which is a rare hereditary disease causing hemolytic anemia.
2. Oncology: - The oncology segment involves the development of therapies aimed at various types of cancer. Agios is deeply invested in understanding the metabolic processes that drive cancer cell growth and survival, leading to the creation of targeted therapies that can selectively inhibit specific metabolic pathways that support tumor growth.
Products
1. Elahere (mirvetuximab soravtansine-gynx): - Approved for the treatment of certain types of ovarian cancer, this drug is an antibody-drug conjugate (ADC) that targets the Folate Receptor Alpha (FRα). It is designed to deliver a potent cytotoxic agent directly to cancer cells that express FRα, thus sparing normal cells and reducing systemic toxicity.
2. AG-348: - This investigational oral medication is under development for the treatment of individuals with PK deficiency. It is designed to restore normal red blood cell function by activating the glycolytic pathway, which is disrupted in patients with this rare genetic condition.
3. AG-636: - An oral therapy in development aimed at treating various types of cancer. It targets mutant isocitrate dehydrogenase (IDH) enzymes found in certain cancers, including acute myeloid leukemia (AML) and glioma. The drug aims to inhibit these enzymes, which are integral to the altered metabolic pathways in cancer cells.
4. AG-221 (Ivosidenib): - Approved for patients with IDH1-mutant relapsed or refractory AML, this targeted therapy works by inhibiting the IDH1 enzyme, which plays a role in tumorigenesis when mutated.
Services
- Clinical Development: - Agios Pharmaceuticals is engaged in extensive clinical trials and studies to assess the safety and efficacy of its drug candidates. The company collaborates with healthcare institutions and partners to facilitate these trials, aiming to bring therapies from the lab to the patient.
- Regulatory Affairs: - The company has a robust regulatory strategy to navigate the complex processes of obtaining approvals from regulatory bodies such as the FDA and EMA. This involves preparing submissions, responding to regulatory inquiries, and ensuring compliance with all regulatory requirements.
- Research and Development: - Agios invests heavily in R&D to explore novel drug candidates and to understand disease mechanisms at the molecular level. Their focus on metabolic pathways provides a unique approach to drug discovery, particularly in oncology and rare diseases.
- Collaborative Partnerships: - The company engages in partnerships with academic institutions and pharmaceutical companies to advance its therapeutic programs. These collaborations may encompass research agreements, co-development arrangements, and licensing deals that can enhance Agios’s drug pipeline and innovation.
With an integrated approach focusing on both rare diseases and cancers, Agios Pharmaceuticals continues to explore innovative therapeutic strategies, aiming to make a significant impact on patients with unmet medical needs.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
100 %